Who
Kristine M. Ball
Director
Company insider
Files Form 4 as: Director, Enliven Therapeutics; Director, Oruka Therapeutics; Director, Atreca; Director, Forty Seven; SVP, Corporate Strategy & CFO, Yarrow Bioscience; Chief Financial Officer & SVP, Relypsa.
In numbers
- Trades disclosed
- 49
- Buys
- 1
- Sells
- 5
- Bought
- $85K
- Sold
- $284K
- Companies
- 6
- Companies where not an officer
- 4
- First trade
- 14 Aug 2014
- Last trade
- 14 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Oct 2026filed 16 Oct 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,394 at $0.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,136 at $0.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,136 at $0.00 | filing |
| 2 Jun 2025filed 3 Jun 2025 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | Atrecaoption or derivative | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 8 Jun 2022filed 10 Jun 2022 | Atrecaoption or derivative | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 9 Jun 2021filed 11 Jun 2021 | Atrecaoption or derivative | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 10 Jun 2020filed 15 Jun 2020 | Atrecaoption or derivative | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 20 May 2020filed 21 May 2020 | Atrecaoption or derivative | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 7 Apr 2020filed 7 Apr 2020 | Forty Sevenoption or derivative | SEC FORM 4 Code D | —69,677 | filing |
| 7 Apr 2020filed 7 Apr 2020 | Forty Sevenoption or derivative | SEC FORM 4 Code D | —10,322 | filing |
| 11 Dec 2019filed 16 Dec 2019 | YARW Yarrow Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code M | —80,300 at $0.00 | filing |
| 11 Dec 2019filed 16 Dec 2019 | YARW Yarrow BioscienceBiotechnology | SEC FORM 4 Code M | —80,300 | filing |
| 11 Dec 2019filed 16 Dec 2019 | YARW Yarrow BioscienceBiotechnology | SEC FORM 4 Code F | $126K27,766 at $4.52 | filing |
| 11 Dec 2019filed 13 Dec 2019 | YARW Yarrow BioscienceBiotechnology | SEC FORM 4 Code M | —80,300 | filing |
| 11 Dec 2019filed 13 Dec 2019 | YARW Yarrow BioscienceBiotechnology | SEC FORM 4 Code F | $126K27,766 at $4.52 | filing |
| 29 Jul 2019filed 7 Aug 2019 | YARW Yarrow Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,300 at $0.00 | filing |
| 29 Jul 2019filed 31 Jul 2019 | YARW Yarrow Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,300 at $0.00 | filing |
| 12 Jun 2019filed 14 Jun 2019 | Forty Sevenoption or derivative | SEC FORM 4 Code A | —10,322 at $0.00 | filing |
| 10 Dec 2018filed 12 Dec 2018 | YARW Yarrow Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —96,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.